Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.172
William Peretti Wobeto, B. Zani, A. Esteves, M. Marangoni, Naiélli da Silva Pinatti, K. Pedro, Nayadne Michaela da Silva, D. Andrade, I. Filho, Uderlei Donizete Silveira Covizzi
Guillain-Barre syndrome (GBS) is an acute demyelinating inflammatory mediated polyneuropathy mediated by the immune system that leads to generalized flaccid paralysis. Most GBS cases are preceded by viral or bacterial infections of the respiratory or gastrointestinal tract, developing an aberrant response that causes autoantibody formation and complement and cytokine activation. Because it is a rare disease, diagnosis is often slow and may worsen the clinical picture. The patient should be evaluated by a multidisciplinary team and the treatment of choice is intravenous human immunoglobulin. We report a case in which the patient had several symptoms resulting from GBS, probably developed by the previous infection, but only had the disease diagnosed late, leading to a worsening of her clinical condition and compromising her quality of life. Since 1976, several studies have established a causal relationship between GBS and vaccines, especially Influenza A, but the pathophysiological mechanism remains unknown. However, it is known that there is a greater chance of GBS development due to Influenza a virus infection than vaccination. Studies reveal that there are environmental and genetic components that may influence susceptibility to disease. However, there is little research on the polymorphism of immune response genes and their influence on the development of the syndrome. Some cases of involvement of people belonging to the same family have been reported in the literature, thus demonstrating that the presence of genetic components influencing the predisposition to GBS cannot be ruled out.
{"title":"Guillain-Barre Syndrome: Case Study and Literature Review","authors":"William Peretti Wobeto, B. Zani, A. Esteves, M. Marangoni, Naiélli da Silva Pinatti, K. Pedro, Nayadne Michaela da Silva, D. Andrade, I. Filho, Uderlei Donizete Silveira Covizzi","doi":"10.35248/1745-7580.19.15.172","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.172","url":null,"abstract":"Guillain-Barre syndrome (GBS) is an acute demyelinating inflammatory mediated polyneuropathy mediated by the immune system that leads to generalized flaccid paralysis. Most GBS cases are preceded by viral or bacterial infections of the respiratory or gastrointestinal tract, developing an aberrant response that causes autoantibody formation and complement and cytokine activation. Because it is a rare disease, diagnosis is often slow and may worsen the clinical picture. The patient should be evaluated by a multidisciplinary team and the treatment of choice is intravenous human immunoglobulin. We report a case in which the patient had several symptoms resulting from GBS, probably developed by the previous infection, but only had the disease diagnosed late, leading to a worsening of her clinical condition and compromising her quality of life. Since 1976, several studies have established a causal relationship between GBS and vaccines, especially Influenza A, but the pathophysiological mechanism remains unknown. However, it is known that there is a greater chance of GBS development due to Influenza a virus infection than vaccination. Studies reveal that there are environmental and genetic components that may influence susceptibility to disease. However, there is little research on the polymorphism of immune response genes and their influence on the development of the syndrome. Some cases of involvement of people belonging to the same family have been reported in the literature, thus demonstrating that the presence of genetic components influencing the predisposition to GBS cannot be ruled out.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"15 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.166
M. Tsuchiya
Mechanism of Low Endotoxin Recovery (LER) was investigated by observing the change in particle sizes and activity of endotoxin in LER solutions containing sodium citrate and polysorbate 20. Interestingly, endotoxin aggregates were not dispersed to be smaller particles under LER conditions according to the decease of the activity. This observation was different from previous predictions of the mechanism. Endotoxin aggregates were observed by Dynamic Light Scattering, and activity was measured by the Limulus amebocyte lysate test. Particles with sizes similar to endotoxin aggregates were always observed despite different remaining activity of spiked endotoxin. This observation differed from previously proposed mechanisms for LER that dispersed endotoxin aggregates were smaller in sizes. Based on the findings, a new mechanism of LER is proposed. Purified endotoxin forms non-lamellar cubic structures in water, and the endotoxin aggregates are reinforced by divalent cations. When purified endotoxin is added to LER solutions, divalent cations are removed from outer layer of endotoxin by the chelating agent, and the loss of divalent cations weakens the outside layer of the endotoxin aggregates. The endotoxin aggregation structure is maintained at low temperature, but endotoxin molecules on the surface of the endotoxin aggregates are gradually replaced with detergent molecules at higher temperature. This replacement reduces the surface area of the endotoxin, and cause reduction of activity of the endotoxin aggregates. The apparent sizes of the aggregates are not changed after the replacement.
{"title":"Mechanism of Low Endotoxin Recovery Caused by a Solution Containing a Chelating Agent and a Detergent","authors":"M. Tsuchiya","doi":"10.35248/1745-7580.19.15.166","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.166","url":null,"abstract":"Mechanism of Low Endotoxin Recovery (LER) was investigated by observing the change in particle sizes and activity of endotoxin in LER solutions containing sodium citrate and polysorbate 20. Interestingly, endotoxin aggregates were not dispersed to be smaller particles under LER conditions according to the decease of the activity. This observation was different from previous predictions of the mechanism. Endotoxin aggregates were observed by Dynamic Light Scattering, and activity was measured by the Limulus amebocyte lysate test. Particles with sizes similar to endotoxin aggregates were always observed despite different remaining activity of spiked endotoxin. This observation differed from previously proposed mechanisms for LER that dispersed endotoxin aggregates were smaller in sizes. Based on the findings, a new mechanism of LER is proposed. Purified endotoxin forms non-lamellar cubic structures in water, and the endotoxin aggregates are reinforced by divalent cations. When purified endotoxin is added to LER solutions, divalent cations are removed from outer layer of endotoxin by the chelating agent, and the loss of divalent cations weakens the outside layer of the endotoxin aggregates. The endotoxin aggregation structure is maintained at low temperature, but endotoxin molecules on the surface of the endotoxin aggregates are gradually replaced with detergent molecules at higher temperature. This replacement reduces the surface area of the endotoxin, and cause reduction of activity of the endotoxin aggregates. The apparent sizes of the aggregates are not changed after the replacement.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.168
A. Manuja, Balvinder Kumar, B. Tripathi
{"title":"Issues and Perspectives in Psoriasis Management","authors":"A. Manuja, Balvinder Kumar, B. Tripathi","doi":"10.35248/1745-7580.19.15.168","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.168","url":null,"abstract":"","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.170
Cristina Sousa, M. Campos, J. D. Lopes, O. Baptista, A. Oliveira
Pemphigus herpetiformis, first described in 1975, is a rare subtype of autoimmune bullous disease that associates clinical features of dermatitis herpetiformis with immunological features of pemphigus. We present a 48-years-old female patient, with pruritic lesions located mainly in the upper limbs with 6 years of evolution. Physical examination revealed erythematous papules, some excoriated and vesicles of translucent content distributed on her arms, trunk and neck. Histological examination of a skin biopsy revealed the presence of sub epidermal vesicles associated with necrosis of the epidermis and perivascular lymphocytic infiltrate in the papillary and reticular dermis. The immunological study was positive for antibodies to intercellular IgG and anti-envoplakin antibodies. Anti-desmoglein 1 and 3 antibodies were negative. Considering these results, the clinical hypothesis of pemphigus herpetiformis was admitted. The positivity of the anti-envoplaquine antibody is often associated with paraneoplastic pemphigus, so a cancer screening was performed which was negative. Prednisolone and dapsone was introduced with resolution of lesions. To our knowledge this is the first clinical case of pemphigus herpetiformis with positive anti-envoplakin antibodies. This rare and often overlooked entity has a good prognosis, although there are cases reports with progression to pemphigus vulgaris or pemphigus foliaceus.
{"title":"Pemphigus Herpetiformis with Only Positive Anti-Envoplakin Antibodies: A Case Report","authors":"Cristina Sousa, M. Campos, J. D. Lopes, O. Baptista, A. Oliveira","doi":"10.35248/1745-7580.19.15.170","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.170","url":null,"abstract":"Pemphigus herpetiformis, first described in 1975, is a rare subtype of autoimmune bullous disease that associates clinical features of dermatitis herpetiformis with immunological features of pemphigus. We present a 48-years-old female patient, with pruritic lesions located mainly in the upper limbs with 6 years of evolution. Physical examination revealed erythematous papules, some excoriated and vesicles of translucent content distributed on her arms, trunk and neck. Histological examination of a skin biopsy revealed the presence of sub epidermal vesicles associated with necrosis of the epidermis and perivascular lymphocytic infiltrate in the papillary and reticular dermis. The immunological study was positive for antibodies to intercellular IgG and anti-envoplakin antibodies. Anti-desmoglein 1 and 3 antibodies were negative. Considering these results, the clinical hypothesis of pemphigus herpetiformis was admitted. The positivity of the anti-envoplaquine antibody is often associated with paraneoplastic pemphigus, so a cancer screening was performed which was negative. Prednisolone and dapsone was introduced with resolution of lesions. To our knowledge this is the first clinical case of pemphigus herpetiformis with positive anti-envoplakin antibodies. This rare and often overlooked entity has a good prognosis, although there are cases reports with progression to pemphigus vulgaris or pemphigus foliaceus.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"96 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.169
Florence Abdallah, C. Pichon
The progression in science gives novel and deeper understandings of human beings organisms. The Human Genome Project uncovered about 20,500 human genes. More recently, non-coding RNAs saw the light and gained researchers interest. Among the different subsets of these non-coding RNAs, microRNAs were identified as 18-25 nucleotides long and have been shown to play critical regulatory roles in a wide range of cellular processes. Emerging studies highlighted the importance of miRNAs in health and in disease. Ten years ago, the role of miRNAs in cutaneous system has been established from skin formation in early life to skin homeostasis maintenance. In addition, a deregulated miRNAs profile was shown to cause major skin disorders. Herein, in this review, a global discussion and findings of the different aspects of miRNAs biology will be covered with a focus on the role of miRNAs in skin biology.
{"title":"MicroRNAs in Skin Biology: Biogenesis, Regulations and Functions in Homeostasis and Diseases","authors":"Florence Abdallah, C. Pichon","doi":"10.35248/1745-7580.19.15.169","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.169","url":null,"abstract":"The progression in science gives novel and deeper understandings of human beings organisms. The Human Genome Project uncovered about 20,500 human genes. More recently, non-coding RNAs saw the light and gained researchers interest. Among the different subsets of these non-coding RNAs, microRNAs were identified as 18-25 nucleotides long and have been shown to play critical regulatory roles in a wide range of cellular processes. Emerging studies highlighted the importance of miRNAs in health and in disease. Ten years ago, the role of miRNAs in cutaneous system has been established from skin formation in early life to skin homeostasis maintenance. In addition, a deregulated miRNAs profile was shown to cause major skin disorders. Herein, in this review, a global discussion and findings of the different aspects of miRNAs biology will be covered with a focus on the role of miRNAs in skin biology.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.167
Annelise de Assis Silva, Maria Antonia Morais de MeloAna Julia Salim Casseb, Maria Eduarda RosaTeles, Victoria Rodrigues Teixeira de Oliveira, J. M. Godoy, Fern, o Batigalia, I. Filho, R. Ramos
Introduction: Lymphedema is characterized by abnormal accumulation of macromolecules and soft tissue fluids. Bioimpedance is a method that measures intra- and extracellular volumes by body segment, and has been currently used in lymphedema. Objective: The objective of this study was to conduct a systematic review of the clinical-therapeutic importance of bioimpedance in patients with lymphedema. Methodology: The present work consisted of a literature review. The systematic review made it possible to know and transcribe important subjects on clinical and therapeutic bioimpedance in patients with lymphedema. The work was carried out from September 2018 to April 2019, following the rules of systematic review – PRISMA. Results: It was found that the variation of the interstitial fluid can be measured by bioimpedance , before and after intensive treatment of lymphedema. Bioimpedance is a noninvasive method used to evaluate interstitial fluids, including indications for lymphedema. Conclusion: Bioimpedance is a suggested method to evaluate clinical and therapeutic follow-up in patients with lymphedema.
{"title":"Clinical-Therapeutic Importance of Bioimpedance in Patients with Lymphedema: A Systematic Review","authors":"Annelise de Assis Silva, Maria Antonia Morais de MeloAna Julia Salim Casseb, Maria Eduarda RosaTeles, Victoria Rodrigues Teixeira de Oliveira, J. M. Godoy, Fern, o Batigalia, I. Filho, R. Ramos","doi":"10.35248/1745-7580.19.15.167","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.167","url":null,"abstract":"Introduction: Lymphedema is characterized by abnormal accumulation of macromolecules and soft tissue fluids. Bioimpedance is a method that measures intra- and extracellular volumes by body segment, and has been currently used in lymphedema. Objective: The objective of this study was to conduct a systematic review of the clinical-therapeutic importance of bioimpedance in patients with lymphedema. Methodology: The present work consisted of a literature review. The systematic review made it possible to know and transcribe important subjects on clinical and therapeutic bioimpedance in patients with lymphedema. The work was carried out from September 2018 to April 2019, following the rules of systematic review – PRISMA. Results: It was found that the variation of the interstitial fluid can be measured by bioimpedance , before and after intensive treatment of lymphedema. Bioimpedance is a noninvasive method used to evaluate interstitial fluids, including indications for lymphedema. Conclusion: Bioimpedance is a suggested method to evaluate clinical and therapeutic follow-up in patients with lymphedema.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.35248/1745-7580.19.15.171
Kangla Tusung
Targeted therapy with small molecule such as TKI (tyrosine kinase inhibitor) against EGFR has achieved high response rate and significant clinical benefits in selected group of lung cancer patients in the past decade. One reliable criterion for patient selection is the presence of certain mutations in the EGFR gene such as mutations in exon-19, 20 or 21 in lung cancer patients. In these patients, it is often observed that TKI therapy could be so effective even against late stage tumors, that patients experience rapid relieve of clinical symptoms and stable control of disease progression for an extended period of time, often lasting for month’s even years.
{"title":"The Presence of Autonomous and Non-Autonomous Replication in Cancer and their Connection through Inflammation: Lessons from one Lung Cancer Case","authors":"Kangla Tusung","doi":"10.35248/1745-7580.19.15.171","DOIUrl":"https://doi.org/10.35248/1745-7580.19.15.171","url":null,"abstract":"Targeted therapy with small molecule such as TKI (tyrosine kinase inhibitor) against EGFR has achieved high response rate and significant clinical benefits in selected group of lung cancer patients in the past decade. One reliable criterion for patient selection is the presence of certain mutations in the EGFR gene such as mutations in exon-19, 20 or 21 in lung cancer patients. In these patients, it is often observed that TKI therapy could be so effective even against late stage tumors, that patients experience rapid relieve of clinical symptoms and stable control of disease progression for an extended period of time, often lasting for month’s even years.","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"15 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69964385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-23DOI: 10.4172/1745-7580-C2-018
Dieter Clemens Broeringp
{"title":"CD55/Crry and complement C3d expression during microvascular rejection in mouse airway allografts","authors":"Dieter Clemens Broeringp","doi":"10.4172/1745-7580-C2-018","DOIUrl":"https://doi.org/10.4172/1745-7580-C2-018","url":null,"abstract":"","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70943850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-23DOI: 10.4172/1745-7580-C2-016
pLuiz WerberB, eirap
{"title":"Primary cutaneous T cell lymphomas: Photochemotherapy immunomodulation with analysis of the inflammatory expansive cellular dynamic","authors":"pLuiz WerberB, eirap","doi":"10.4172/1745-7580-C2-016","DOIUrl":"https://doi.org/10.4172/1745-7580-C2-016","url":null,"abstract":"","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70943797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-15DOI: 10.4172/1745-7580-c3-019
pGeert C Muddep
{"title":"Next generation immuno-therapy: tumour specific control of immune checkpoints","authors":"pGeert C Muddep","doi":"10.4172/1745-7580-c3-019","DOIUrl":"https://doi.org/10.4172/1745-7580-c3-019","url":null,"abstract":"","PeriodicalId":73347,"journal":{"name":"Immunome research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43766813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：